A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial results with less than half the dose. Medscape Medical News
Peptidomimetics, synthetically modified peptides which have been engineered to eliminate certain undesirable features of native therapeutic peptides including short half-lives, immunogenicity, and delivery challenges, are a growing class of peptide-based therapeutics. Azapeptides (C to N substitution(s)), a type of peptidomimetic with several examples in clinical use, are known to exhibit increased resistance to endogenous proteases, … Read more
A recent study presented at the European Congress on Obesity reveals that individuals using weight loss drugs, including newer GLP-1 medications, tend to regain all lost weight within a year of discontinuing the medication. While these drugs effectively induce weight loss, maintaining a healthy lifestyle through diet and exercise remains crucial for long-term success.
The cost of prescription drugs in the U.S. has long outpaced that of peer nations, a dynamic driven by a combination of regulatory gaps, market forces, and lobbying pressure. Now, President Donald Trump is once again trying to tackle the issue—this time through an Executive Order that aims to pressure pharmaceutical companies to voluntarily lower … Read more
This systematic review and meta-analysis examines data for patients with diabetes and/or obesity from trials of GLP1-RA treatment to evaluate psychiatric, cognitive, and quality-of-life outcomes compared with placebo.
Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025 Mar;49(3):452-463. doi: 10.1038/s41366-024-01599-z. Epub 2024 Aug 10. PMID: 39127792; PMCID: PMC11931505. Published 10 August 2024 This review article explores the potential of precision medicine to improve obesity management, moving away from the current trial-and-error approach for selecting medications. … Read more
Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk. Obesity is a known risk factor for certain types of cancers, and has also been shown to impact cancer survival. Obesity-related cancers include multiple myeloma, … Read more
By AL LEWIS Last month Aon, the major benefits consulting firm, released a “study” claiming: A significant opportunity to reduce healthcare costs for employers and enhance overall workforce health through a comprehensive obesity management program that includes GLP-1 medications. This, of course, is the opposite of what most researchers have shown. And in the immortal … Read more
Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a potential role for dermatologists in obesity management. Medscape Medical News
In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or full dosing was achieved. Medscape Medical News